Translation: Original published in Finnish on 5/20/2026 at 6:56 am EEST.

Herantis announced on Tuesday that it had entered into a collaboration agreement with Switzerland-based Indivi for the integration of its digital biomarker platform in the upcoming Phase II study of the HER-096 drug candidate. The news is an anticipated step forward in trial design, as we have previously estimated that the company planned to use digital methods to monitor patients' symptoms. This technology can improve the study's sensitivity to detect potential treatment effects within a relatively short follow-up period.

Indivi's technology uses smartphone-based assessments of motor and cognitive function, enabling more frequent and sensitive symptom monitoring than traditional clinical methods. Parkinson's disease typically progresses slowly, making it challenging to demonstrate the drug's potential efficacy in a Phase II trial, which we estimate will last approximately 6–12 months. Incorporating digital tools into the upcoming study is indeed welcome because they can improve the study’s signal-to-noise ratio and help identify more acute treatment effects. In practice, we believe the tool increases the likelihood of identifying a potential treatment response, which could help facilitate the conduct and funding of a Phase III trial aimed at obtaining marketing authorization. Similar digital tools have already been utilized in drug development in this field, such as in Roche’s ongoing Phase III Parkinson’s study. Herantis aims to initiate the Phase II study during 2026, for which additional funding is still needed.